<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>321</serviceExecutionTime><Drug id="100019"><DrugName>HOB-071</DrugName><DrugSynonyms><Name><Value>HOB-071</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DPP-IV + ARB (diabetic hyperlipidemia), Hyundai Pharma</Value></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"/><TargetEntity id="D006949" type="MeSH"/><TargetEntity id="-1908196798" type="omicsDisease"/><TargetEntity id="971" type="siCondition"/></SourceEntity><SourceEntity id="64" type="Action"><TargetEntity id="3578" type="Mechanism">Anti-Angiotensin II</TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00618" type="ciTarget"><TargetEntity id="17367845618033" type="siTarget">Dipeptidyl peptidase 4</TargetEntity><TargetEntity id="8056" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="64">Angiotensin II receptor antagonist</Action><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9C</Code><Name>ANGIOTENSIN-II ANTAGONISTS, PLAIN</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:20:11.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HOB-071, a dipeptidyl peptidase-IV (DPP-IV) inhibitor and an angiotensin II receptor antagonist (ARB), for the potential treatment of diabetic hyperlipidemia [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. In November 2015, the program was in the discovery stage [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00139"><Name>Angiotensin II receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00618"><Name>Dipeptidyl peptidase IV</Name><SwissprotNumbers><Swissprot>P14740</Swissprot><Swissprot>P22411</Swissprot><Swissprot>P27487</Swissprot><Swissprot>P28843</Swissprot><Swissprot>P81425</Swissprot><Swissprot>Q9N2I7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100043"><DrugName>DHX-11</DrugName><DrugSynonyms><Name><Value>DHX-11</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004998">Shenyang Pharmaceutical University</CompanyOriginator><CompaniesSecondary><Company id="1004998">Shenyang Pharmaceutical University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1004998" type="Company"><TargetEntity id="5035524415" type="organizationId">Shenyang Pharmaceutical University</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-05-30T05:50:41.000Z</LastModificationDate><ChangeDateLast>2018-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1004998" linkType="Company"&gt;Shenyang Pharmaceutical University&lt;/ulink&gt;   was investigating DHX-11, for the potential treatment of cancer. In November 2015, it was in preclinical studies; at that time, the university was seeking to outlicense this project [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015,  the university intended to develop DHX-11 as a class 1.1 drug in China  [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2012, preclinical data in rats were published  [&lt;ulink linkID="1716193" linkType="Reference"&gt;1716193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By January 2012, the project was funded by Liaoning government [&lt;ulink linkID="1716191" linkType="Reference"&gt;1716191&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-05-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1716191" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>3 references added [&lt;ulink url="utility.reference?i_reference_id=1716193" linkType="reference" linkID="1716193"&gt;1716193&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1708648" linkType="reference" linkID="1708648"&gt;1708648&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1716191" linkType="reference" linkID="1716191"&gt;1716191&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>